Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 4/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617431 | 1.00 | DDB1 (0.38) | DDB1CRBNBRD4CREBBPIRAK4 | |
| SCHEMBL28903468 | 0.84 | DDB1 (0.35) | DDB1CRBNBRD4CREBBPIRAK4 | |
| SCHEMBL38664462 | 0.83 | DDB1 (0.34) | DDB1CRBNIRAK4LMNATACR1 | |
| SCHEMBL25664268 | 0.83 | DDB1 (0.34) | DDB1CRBNIRAK4LMNATACR1 | |
| SCHEMBL24687471 | 0.81 | DDB1 (0.33) | DDB1CRBNIRAK4LMNATACR1 | |
| SCHEMBL24722595 | 0.76 | DDB1 (0.33) | DDB1CRBNIRAK4 | |
| SCHEMBL14473849 | 0.74 | GHSR (0.38) | — | |
| SCHEMBL22001577 | 0.74 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL15358117 | 0.74 | GHSR (0.38) | — | |
| SCHEMBL16529770 | 0.74 | GHSR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | DDB1 562/4885CRBN 1869/4885BRD4 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.